Home > In process > Clinical course and prognosis of chronic autoimmune neuropathies requiring intensive care: a retrospective cohort study. > print

001     285465
005     20260306132023.0
024 7 _ |a 10.1007/s00415-026-13694-4
|2 doi
024 7 _ |a pmid:41739210
|2 pmid
024 7 _ |a pmc:PMC12935830
|2 pmc
024 7 _ |a 0367-004X
|2 ISSN
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
037 _ _ |a DZNE-2026-00243
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Preßler, Hannah
|0 P:(DE-2719)9003388
|b 0
|e First author
245 _ _ |a Clinical course and prognosis of chronic autoimmune neuropathies requiring intensive care: a retrospective cohort study.
260 _ _ |a [Darmstadt]
|c 2026
|b Steinkopff
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772799424_9735
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Data on chronic autoimmune neuropathies (CAN) requiring intensive care unit (ICU) treatment are limited. This study investigated clinical and neuropathological features, immunotherapies, and outcomes of ICU-treated CAN patients.Retrospectively, we analyzed patients with CAN admitted to the ICU between 2007 and 2024. Outcomes, assessed by Inflammatory Neuropathy Cause and Treatment (INCAT) score and modified Rankin scale (mRS), were compared to age, sex, and diagnosis-matched non-ICU outpatients using ordinal and binary logistic regression.Among 21 included patients (chronic inflammatory demyelinating neuropathies (CIDP): n = 15, other CAN: n = 6), 95% required mechanical ventilation and exhibited severe tetraparesis at disease nadir. Biopsies from CIDP patients revealed moderate-to-severe chronic axonal loss with variable CD8 + T-cell infiltration (9/11), and complement deposition (C5b-9) was detected in all samples (n = 8/8). All patients received first-line immunotherapy at ICU, 62% required 'escalation' (rituximab: n = 13, cyclophosphamide: n = 3). Five (24%) remained refractory, receiving daratumumab (n = 3), efgartigimod (n = 1), or autologous stem cell transplantation (n = 1). Six patients (29%) died, whereas survivors showed marked improvement with median change of - 2 mRS points (95% CI - 5 to - 2) and - 6 INCAT points (95% CI - 8 to- 5) at last follow-up. However, ICU-treated patients had significantly higher odds of worse long-term outcomes than matched non-ICU patients (adjusted cumulative OR: mRS 7.1 95% CI 1.9-27.3, INCAT 6.4 95% CI 1.7-23.2).Severe CAN requiring ICU treatment is associated with high mortality, but meaningful recovery is possible in survivors. Neuropathology confirmed combined cellular and humoral mechanisms, supporting personalized, mechanism-guided therapeutic approaches.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Autologous stem cell transplantation
|2 Other
650 _ 7 |a Chronic autoimmune neuropathies
|2 Other
650 _ 7 |a Daratumumab
|2 Other
650 _ 7 |a Intensive care unit
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a Critical Care
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: therapy
|2 MeSH
650 _ 2 |a Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: diagnosis
|2 MeSH
650 _ 2 |a Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: pathology
|2 MeSH
650 _ 2 |a Immunotherapy
|2 MeSH
650 _ 2 |a Intensive Care Units
|2 MeSH
650 _ 2 |a Autoimmune Diseases of the Nervous System: therapy
|2 MeSH
650 _ 2 |a Autoimmune Diseases of the Nervous System: diagnosis
|2 MeSH
700 1 _ |a Schwarz, Lisa
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Streit, Simon
|0 0009-0008-0101-8081
|b 2
700 1 _ |a Aigner, Annette
|0 0000-0003-4891-8921
|b 3
700 1 _ |a Schleicher, Alicia
|b 4
700 1 _ |a Stascheit, Frauke
|0 0000-0001-5306-7880
|b 5
700 1 _ |a Arlt, Friederike A
|0 P:(DE-2719)9002282
|b 6
700 1 _ |a Zinnow, Viktoria
|0 P:(DE-2719)9003096
|b 7
|u dzne
700 1 _ |a Khorassani, Tatjana
|b 8
700 1 _ |a Prüss, Harald
|0 P:(DE-2719)2810931
|b 9
700 1 _ |a Böhmerle, Wolfgang
|b 10
700 1 _ |a Meisel, Andreas
|b 11
700 1 _ |a Stenzel, Werner
|b 12
700 1 _ |a Scheibe, Franziska
|b 13
773 _ _ |a 10.1007/s00415-026-13694-4
|g Vol. 273, no. 2, p. 165
|0 PERI:(DE-600)1421299-7
|n 2
|p 165
|t Journal of neurology
|v 273
|y 2026
|x 0367-004X
856 4 _ |u https://pub.dzne.de/record/285465/files/DZNE-2026-00243.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285465/files/DZNE-2026-00243.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9003388
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9002282
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9003096
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810931
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Encephalopathies
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1810003
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21